Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy

NCT01916720 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerosis

Interventions

DRUG: SB-480848 40 mg
DRUG: SB-480848 80 mg
DRUG: Placebo

Sponsor

GlaxoSmithKline